Bevespi Aerosphere Patent Expiration

Bevespi Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 7 US drug patents filed from 2016 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 17, 2031. Details of Bevespi Aerosphere's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324266 Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

Active
US10716753 Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

Active
US9415009 Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

Active
US8703806 Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(5 years from now)

Active
US8808713 Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

Active
US9463161 Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(5 years from now)

Active
US8815258 Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)

Active


FDA has granted several exclusivities to Bevespi Aerosphere. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Bevespi Aerosphere, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Bevespi Aerosphere.

Exclusivity Information

Bevespi Aerosphere holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Bevespi Aerosphere's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Bevespi Aerosphere is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bevespi Aerosphere's family patents as well as insights into ongoing legal events on those patents.

Bevespi Aerosphere's family patents

Bevespi Aerosphere has patent protection in a total of 31 countries. It's US patent count contributes only to 14.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Bevespi Aerosphere.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Bevespi Aerosphere's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 17, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Bevespi Aerosphere Generics:

There are no approved generic versions for Bevespi Aerosphere as of now.





About Bevespi Aerosphere

Bevespi Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere uses Formoterol Fumarate; Glycopyrrolate as an active ingredient. Bevespi Aerosphere was launched by Astrazeneca in 2016.

Market Authorisation Date:

Bevespi Aerosphere was approved by FDA for market use on 25 April, 2016.

Active Ingredient:

Bevespi Aerosphere uses Formoterol Fumarate; Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Formoterol Fumarate; Glycopyrrolate ingredient

Treatment:

Bevespi Aerosphere is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Dosage:

Bevespi Aerosphere is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.0048MG/INH;0.0090MG/INH AEROSOL, METERED Prescription INHALATION